NEW YORK (GenomeWeb News) – Novo Nordisk has licensed gene expression technology from TET Systems for use in its research activities, TET Systems said.

Under the agreement, Novo Nordisk will use TET Systems technology at the Hagedorn Research Institute, which handles the drug developer's internal research activities.

Heidelberg, Germany-based TET Systems holds six patent families of intellectual property covering methods to control gene expression in higher organisms.

Financial terms of the agreement were not released.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Jackson Laboratory has filed a complaint accusing Nanjing University of breeding and re-selling its mouse models, the Hartford Courant reports.

Oxford researchers are turning to virtual reality to visualize genes and regulatory elements, Phys.org says.

In Science this week: neutrophils rely on microRNA to protect against lung inflammation, and more.

China is moving forward with plans to sequence a million citizens, the Wall Street Journal reports.